| |
MESSAGE _ENGLISH VERSION_
|
|
| |
Conclusion of a letter of intent for the development of a minimally
invasive robotic system for the treatment of structural heart defects
Current report no.: 18/2026
Date: May 13, 2026
Legal basis: Article 17_1_ of the MAR Regulation - confidential
information
Management Board of Medicalgorithmics S.A. with its registered office in
Warsaw _the "Company"_ informs that on 13 May 2026, the Company has
entered into a letter of intent _the "Letter of Intent"_ with the
Zbigniew Religa Foundation for the Development of Cardiac Surgery
_"FRK"_ and the Company's shareholder Biofund Capital Management LLC
_"BioFund"_, _collectively, the "Parties"_ relating to the planned
cooperation of the Parties in connection with the potential
implementation of a project involving the design, development and
commercialization of a next-generation minimally invasive robotic system
intended for the treatment of structural heart defects _the "Project"_.
The Letter of Intent is non-binding, except for the provisions relating
to negotiation exclusivity, confidentiality and public communications,
which are binding, and constitutes an expression of the Parties'
intention to jointly pursue the Project on the terms set forth therein.
In accordance with its provisions, the cooperation is intended to
include, in particular, activities involving the design, development and
potential commercialization of solutions combining medical imaging
analysis software, robotic systems and elements supporting clinical
workflows.
The Parties have indicated, inter alia, that in order to implement the
Project they intend to carry out further conceptual, technical and
organizational work, including determining the cooperation model _in
particular, the possible establishment of a joint entity_, the
principles for the Parties' contributions _including technology,
know-how and funding_, as well as the framework for commercialization of
the Project. The Parties have also outlined general assumptions
regarding intellectual property principles applicable to the Project.
The detailed terms of cooperation are to be specified in separate,
binding agreements.
The Parties have further agreed to conduct exclusive negotiations with
respect to the Project for a period of 90 days from the date of
execution of the Letter of Intent. At the same time, the Company
indicates that as of the date of publication of this report no binding
agreements regarding the implementation of the Project have been
concluded, and the undertaking of further actions, including the
execution of definitive agreements, is subject to the results of ongoing
analyses and negotiations between the Parties and is not certain.
In the opinion of the Management Board, the execution of the Letter of
Intent constitutes a significant event for the Company, as it aligns
with the development of the Company's strategic business directions and
may represent an important step towards building therapeutic
capabilities in the field of cardiac surgery, which, if definitive
agreements are concluded and the Project is implemented, may impact the
development of the Company's business operations and its growth
prospects.
|
|
|
RB: Zawarcie listu intencyjnego w zakresie rozwoju minimalnie inwazyjnego systemu robotycznego
do leczenia strukturalnych wad serca
